Infinity Flight Group Expands Its Training Fleet With 10 Additional Cessna Skyhawks, Boosting Training Capabilities for Future Pilots
A certified Cessna Pilot Center, Infinity Flight Group currently operates 65 Cessna Skyhawks out of their bases at Trenton-Mercer Airport in New Jersey and Treasure Coast Airport in Ft. Pierce, Florida. The additional aircraft will join the flight school's current fleet of Cessna Skyhawks, enhancing its capacity to train the next generation of aviators.
'The Cessna Skyhawk sets the standard in reliability and performance,' said Chris Crow, vice president, Piston Sales. 'Organizations like Infinity Flight Group continue to place trust in this industry-leading aircraft, which is ideal for both student pilots and private owners.'
The best-selling, high-wing piston has earned a reputation for reliability, ease of use, and versatility over the decades, making it a favorite among flight schools and experienced pilots. Infinity Flight Group's new aircraft will feature the recently announced dual electronic ignition system (dual EIS), enhancing maintenance, efficiency and overall operation of the Skyhawk. As Textron Aviation celebrates the Cessna 172 Skyhawk's 70th anniversary this year, this continued investment in innovation underscores the aircraft's exceptional design and enduring capabilities, marking seven decades since its first flight in June 1955.
About the Cessna Skyhawk
The Cessna Skyhawk is considered the aircraft of choice for pilot training, and it is the most popular single-engine aircraft in aviation history. Since the aircraft first took flight in 1955, over 45,000 Skyhawks have been delivered to customers around the world – more than any other aircraft in the industry. The single-engine four-seat, high-wing Skyhawk is renowned for offering the best combination of modern features, including the Garmin G1000 NXi avionics with wireless connectivity, a standard angle-of-attack display system, and proven dependability. The aircraft also features a McCauley aluminum fixed pitch propeller.
About Textron Aviation
We inspire the journey of flight. For more than 95 years, Textron Aviation Inc., a Textron Inc. company, has empowered our collective talent across the Beechcraft, Cessna and Hawker brands to design and deliver the best aviation experience for our customers. With a range that includes everything from business jets, turboprops, and high-performance pistons, to special mission, military trainer and defense products, Textron Aviation has the most versatile and comprehensive aviation product portfolio in the world and a workforce that has produced more than half of all general aviation aircraft worldwide. Customers in more than 170 countries rely on our legendary performance, reliability and versatility, along with our trusted global customer service network, for affordable and flexible flight.
For more information, visit www.txtav.com | www.defense.txtav.com | www.scorpionjet.com.
About Textron Inc.
Textron Inc. is a multi-industry company that leverages its global network of aircraft, defense, industrial and finance businesses to provide customers with innovative solutions and services. Textron is known around the world for its powerful brands such as Bell, Cessna, Beechcraft, Pipistrel, Jacobsen, Kautex, Lycoming, E-Z-GO, and Textron Systems. For more information, visit: www.textron.com.
Certain statements in this press release are forward-looking statements which may project revenues or describe strategies, goals, outlook or other non-historical matters; these statements speak only as of the date on which they are made, and we undertake no obligation to update or revise any forward-looking statements. These statements are subject to known and unknown risks, uncertainties, and other factors that may cause our actual results to differ materially from those expressed or implied by such forward-looking statements, including, but not limited to changes in aircraft delivery schedules or cancellations or deferrals of orders.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Why Anheuser-Busch InBev Stock Crashed Today
Key Points Anheuser-Busch InBev reported declining volumes of beer shipped in Q2. Revenue still increased, and at least one version of earnings was up. GAAP profits fell far short of what the company calls its "underlying profit." 10 stocks we like better than Anheuser-Busch InBev/NV › Shares of Anheuser-Busch InBev (NYSE: BUD), the multinational beverages (specifically, beer) stock, tumbled 11.8% through 10:05 a.m. ET Thursday after the company reported declining volumes of beer shipped in the second quarter and weaker-than-expected revenue. Analysts had forecast Anheuser-Busch would earn $0.95 per share on $15.3 billion in sales. Earnings edged out expectations at $0.98, but revenue was only $15 billion. Anheuser-Busch InBev Q2 earnings Not all the news was bad. Anheuser-Busch InBev noted that actual revenue increased 3% year over year in Q2, and "normalized EBITDA" was up 6.5%, with EBITDA margins expanding to 35.3%. Reported revenue, however, was hurt by unfavorable currency exchange rates, meaning a weak U.S. dollar. That depressed real revenue growth to just 2.1%. The company said its "underlying profit" grew 7.7% to $1.95 billion, and underlying earnings per share grew 8.7% as the company bought back stock in the quarter. At Anheuser-Busch InBev, "underlying profit" basically translates as non-GAAP (adjusted) earnings, however -- and investors are treating the numbers as such. Anheuser-Busch doesn't make it easy to figure out what its actual earnings as calculated according to generally accepted accounting principles (GAAP) were, but according to data from S&P Global Market Intelligence, they were only $0.82 per share. Is Anheuser-Busch InBev stock a buy? And now you see why investors are upset. Whatever the "underlying" or "normalized EBITDA" numbers say, Anheuser-Busch InBev's actual profit for Q2 was 16% lower than the headline number. Granted, the stock doesn't look too expensive at just over 18 times earnings. But analysts only see the stock growing earnings at 12.5% over the next five years -- and right now, earnings are heading in the opposite direction, not growing, but shrinking. And with a trend like that, it's hard to call the stock a buy. Should you invest $1,000 in Anheuser-Busch InBev/NV right now? Before you buy stock in Anheuser-Busch InBev/NV, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Anheuser-Busch InBev/NV wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $638,629!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,098,838!* Now, it's worth noting Stock Advisor's total average return is 1,049% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Rich Smith has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Anheuser-Busch InBev Stock Crashed Today was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
22 minutes ago
- Yahoo
Bristol-Myers Squibb (NYSE:BMY) Reports Strong Q2, Full-Year Sales Guidance is Optimistic
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced better-than-expected revenue in Q2 CY2025, but sales were flat year on year at $12.27 billion. The company's full-year revenue guidance of $47 billion at the midpoint came in 1.6% above analysts' estimates. Its non-GAAP profit of $1.46 per share was 32.6% above analysts' consensus estimates. Is now the time to buy Bristol-Myers Squibb? Find out in our full research report. Bristol-Myers Squibb (BMY) Q2 CY2025 Highlights: Revenue: $12.27 billion vs analyst estimates of $11.38 billion (flat year on year, 7.8% beat) Adjusted EPS: $1.46 vs analyst estimates of $1.10 (32.6% beat) The company lifted its revenue guidance for the full year to $47 billion at the midpoint from $46.3 billion, a 1.5% increase Management lowered its full-year Adjusted EPS guidance to $6.50 at the midpoint, a 5.1% decrease Operating Margin: 14.5%, up from 12.8% in the same quarter last year Market Capitalization: $93.57 billion Company Overview With roots dating back to 1887 and a transformative merger in 1989 that gave the company its current name, Bristol-Myers Squibb (NYSE:BMY) discovers, develops, and markets prescription medications for serious diseases including cancer, blood disorders, immunological conditions, and cardiovascular diseases. Revenue Growth Examining a company's long-term performance can provide clues about its quality. Any business can have short-term success, but a top-tier one grows for years. Regrettably, Bristol-Myers Squibb's sales grew at a mediocre 6.5% compounded annual growth rate over the last five years. This was below our standard for the healthcare sector and is a tough starting point for our analysis. We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. Bristol-Myers Squibb's recent performance shows its demand has slowed as its annualized revenue growth of 2.7% over the last two years was below its five-year trend. We can better understand the company's revenue dynamics by analyzing its most important segment, Growth Portfolio. Over the last two years, Bristol-Myers Squibb's Growth Portfolio revenue averaged 17.4% year-on-year growth. This segment has outperformed its total sales during the same period, lifting the company's performance. This quarter, Bristol-Myers Squibb's $12.27 billion of revenue was flat year on year but beat Wall Street's estimates by 7.8%. Looking ahead, sell-side analysts expect revenue to decline by 5.8% over the next 12 months, a deceleration versus the last two years. This projection is underwhelming and suggests its products and services will face some demand challenges. Software is eating the world and there is virtually no industry left that has been untouched by it. That drives increasing demand for tools helping software developers do their jobs, whether it be monitoring critical cloud infrastructure, integrating audio and video functionality, or ensuring smooth content streaming. Click here to access a free report on our 3 favorite stocks to play this generational megatrend. Operating Margin Operating margin is one of the best measures of profitability because it tells us how much money a company takes home after subtracting all core expenses, like marketing and R&D. Bristol-Myers Squibb was profitable over the last five years but held back by its large cost base. Its average operating margin of 9.1% was weak for a healthcare business. On the plus side, Bristol-Myers Squibb's operating margin rose by 6.9 percentage points over the last five years, as its sales growth gave it operating leverage. Zooming into its more recent performance, however, we can see the company's margin has decreased by 1.6 percentage points on a two-year basis. If Bristol-Myers Squibb wants to pass our bar, it must prove it can expand its profitability consistently. In Q2, Bristol-Myers Squibb generated an operating margin profit margin of 14.5%, up 1.7 percentage points year on year. This increase was a welcome development and shows it was more efficient. Earnings Per Share We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company's growth is profitable. Bristol-Myers Squibb's EPS grew at an unimpressive 3.2% compounded annual growth rate over the last five years, lower than its 6.5% annualized revenue growth. We can see the difference stemmed from higher interest expenses or taxes as the company actually improved its operating margin and repurchased its shares during this time. In Q2, Bristol-Myers Squibb reported adjusted EPS at $1.46, down from $2.07 in the same quarter last year. Despite falling year on year, this print easily cleared analysts' estimates. Over the next 12 months, Wall Street expects Bristol-Myers Squibb's full-year EPS of $6.73 to shrink by 5%. Key Takeaways from Bristol-Myers Squibb's Q2 Results We were impressed by how significantly Bristol-Myers Squibb blew past analysts' EPS expectations this quarter. We were also excited its revenue outperformed Wall Street's estimates by a wide margin. On the other hand, full-year EPS guidance was lowered. Zooming out, we think this was a mixed print. The market seemed to be hoping for more, and the stock traded down 3.9% to $44.21 immediately following the results. Should you buy the stock or not? We think that the latest quarter is just one piece of the longer-term business quality puzzle. Quality, when combined with valuation, can help determine if the stock is a buy. We cover that in our actionable full research report which you can read here, it's free. Sign in to access your portfolio
Yahoo
22 minutes ago
- Yahoo
Dream Finders Homes: Riding Out the Storm
Key Points Dream Finders reported solid growth in revenue and home closings, but higher expenses weighed on earnings. The company is following its playbook through the downturn, completing two acquisitions in the quarter. Dream Finders has ample resources to be opportunistic while housing is slow, but investors shouldn't expect a turnaround until macro forces realign and home buyers return to the market. 10 stocks we like better than Dream Finders Homes › Here's our initial take on Dream Finders Homes (NYSE: DFH) financial report. Key Metrics Metric Q2 2024 Q2 2025 Change vs. Expectations Revenue $1.06 billion $1.15 billion 9% Beat Earnings per share $0.81 $0.56 (31%) Missed Home closings 2,031 2,232 10% n/a Net new orders 1,712 1,938 13% n/a Dream Finders Remains On Course Despite Difficult Market Dream Finders grew revenue by 9% and home closings by 10% in what is a difficult housing environment, but higher homebuilding cost of sales and financial services expense ate into profitability. Homebuilding gross margin fell 250 basis points to 16.5%. Elevated interest rates, an uncertain economy, and pressures from soaring costs on home building supplies and labor have created what CEO Patrick Zalupski called "perhaps the most challenging environment in the past three years." Dream Finders continues to execute on its plan despite the downturn. In the quarter, the company closed deals for Alliant National Title Insurance Co. and Green River Builders, bringing its total to 10 acquisitions in the past six years. Alliant opens up new revenue sources, while Green River expands Dream Finders' presence in the fast-growing Atlanta area. The company also repurchased more than 700,000 shares for $16 million during the period. Immediate Market Reaction Investors knew going in that this was a tough housing market, and the results had little impact on sentiment. Dream Finders stock is down about 1% in early Thursday trading. What to Watch The big question facing homebuilders is when the housing market will turn. On Wednesday, the Federal Reserve held rates steady, and the odds of a September rate cut fell slightly, opening up the possibility of higher for longer on interest rates. Dream Finders ended the quarter with a backlog of 2,513 homes valued at $1.2 billion and reiterated its guidance for about 9,250 home closings in 2025. If the market remains weak, expect the company to continue to hunt for acquisition candidates in its core Sun Belt markets in anticipation of an eventual turnaround. The company cannot control the macro environment, and it is unlikely to see oversized growth until buyers return. But Dream Finders appears to be holding serve in a difficult climate, which is about the best investors can hope for for now. Helpful Resources Full earnings report Investor relations page Additional coverage Should you invest $1,000 in Dream Finders Homes right now? Before you buy stock in Dream Finders Homes, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Dream Finders Homes wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $638,629!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,098,838!* Now, it's worth noting Stock Advisor's total average return is 1,049% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Lou Whiteman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Dream Finders Homes. The Motley Fool has a disclosure policy. Dream Finders Homes: Riding Out the Storm was originally published by The Motley Fool Sign in to access your portfolio
